The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
Open accessAbstract
Interleukin 17A (IL-17A) is one of the currently known six members of the IL-17 cytokine family and is implicated in immune responses to infectious pathogens and in the pathogenesis of inflammatory autoimmune diseases like psoriasis. Psoriatic skin is characterized by high expression of IL-17A and IL-17F, which act on immune and non-immune cell types and strongly contribute to tissue inflammation. In psoriatic lesions, IL-17A, IL-17E, and IL-17F are involved in neutrophil accumulation, followed by the formation of epidermal micro abscesses. IL-17A together with other Th17 cytokines also upregulates the production of several chemokines that are implicated in psoriasis pathogenesis. IL17A-targeting antibodies show an impressive clinical efficacy in patients with psoriasis. Studies have reported an improvement of at least 75% as measured by the psoriasis area and severity index (PASI) in >80% of patients treated with anti-IL-17A therapy. Psoriasis skin manifestations, cardiovascular as well as metabolic disease in psoriasis appear to share pathogenic mechanisms evolving around IL-17A and its proinflammatory role. Thus, anti-IL-17A therapy not only improves skin manifestations of psoriasis, but also cardiovascular inflammation as well as metabolic factors and different domains of psoriatic arthritis (PsA) including peripheral arthritis, enthesitis, dactylitis, and axial involvement. This review summarizes the biological role of IL-17A, before reviewing currently available data on its role in the physiology and pathophysiology of the skin, as well as the cardiovascular and the metabolic system. In conclusion, clinical recommendations for patients with moderate to severe psoriasis based on the current available data are given.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199 · cited 3×
“Similarly, stress pathways such as hypoxia, reactive oxygen species (ROS), endoplasmic reticulum activation, lipids, fatty acids, and cytokines are integrated with insulin signaling via inhibitory mechanisms by c-Jun N-terminal kinase (JNK) activation (120).”
BackgroundInfluentialInflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Adipokines in inflammation and metabolic disease
Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011) · Nature Reviews Immunology · doi:10.1038/nri2921 · Cited by 4,625
Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L., & Spiegelman, B. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117936 · Cited by 3,543
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997 · cited 2×
“treatment in head-to-head double-blind randomized trials was superior to established biological treatments like etanercept (TNF inhibitor) and ustekinumab (anti-IL12/23), raising the bar, where more than 80% of the patients achieved a PASI 90 and DLQI of 0/1 (35, 41, 42).”
BackgroundMethodThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585
Structure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475
Targeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414 · cited 1×
“Importantly, targeting IL-17A is also effective in psoriatic arthritis, demonstrating that the psoriatic inflammation at distant sites also depends on the action of IL-17A (52).”
BackgroundSodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells
Kleinewietfeld, M., Manzel, A., Titze, J., Kvakan, H., Yosef, N., Linker, R. A., Muller, D. N., & Hafler, D. A. (2013) · Nature · doi:10.1038/nature11868 · Cited by 1,394
Generation of pathogenic TH17 cells in the absence of TGF-β signalling
Ghoreschi, K., Laurence, A., Yang, X.-P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L., Wei, L., Davidson, T. S., Bouladoux, N., et al. (2010) · Nature · doi:10.1038/nature09447 · Cited by 1,388
Self-citationLow-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
Macrophage-mediated inflammation in metabolic disease
Chawla, A., Nguyen, K. D., & Goh, Y. P. S. (2011) · Nature reviews. Immunology · doi:10.1038/nri3071 · Cited by 1,314
IL-17 regulates adipogenesis, glucose homeostasis, and obesity
Zúñiga, L. A., Shen, W.-J., Joyce-Shaikh, B., Pyatnova, E. A., Richards, A. G., Thom, C., Andrade, S. M., Cua, D. J., Kraemer, F. B., & Butcher, E. C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001269 · Cited by 394
PRODANOWICH, S., MA, F., TAYLOR, J., PEZON, C., FASIHI, T., & KIRSNER, R. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.06.017 · Cited by 384
Baldeviano, G. C., Barin, J. G., Talor, M. V., Srinivasan, S., Bedja, D., Zheng, D., Gabrielson, K., Iwakura, Y., Rose, N. R., & Cihakova, D. (2010) · Circulation Research · doi:10.1161/circresaha.109.213157 · Cited by 334 · cited 2×
“IL-17RA mice were protected from inducing DCM, although they developed myocarditis comparable to WT controls (104).”
BackgroundListing, J., Kekow, J., Manger, B., Burmester, G.-R., Pattloch, D., Zink, A., & Strangfeld, A. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204021 · Cited by 295
Innate immunity and adipose tissue biology
Schäffler, A., & Schölmerich, J. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.03.001 · Cited by 283
Self-citationCardiac fibroblasts mediate IL-17A–driven inflammatory dilated cardiomyopathy
Wu, L., Ong, S., Talor, M. V., Barin, J. G., Baldeviano, G. C., Kass, D. A., Bedja, D., Zhang, H., Sheikh, A., Margolick, J. B., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20132126 · Cited by 181
Liu, Y., Zhu, H., Su, Z., Sun, C., Yin, J., Yuan, H., Sandoghchian, S., Jiao, Z., Wang, S., & Xu, H. (2012) · International Immunology · doi:10.1093/intimm/dxs056 · Cited by 110
Straub, R. H. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.08.002 · Cited by 69
Cited by
Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences
Boehncke, W.-H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00579 · Cited by 307
Self-citationAngiogenesis in Chronic Inflammatory Skin Disorders
Lee, H. J., Hong, Y. J., & Kim, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112035 · Cited by 211
Stewart, A., Ng, J. C.-F., Wallis, G., Tsioligka, V., Fraternali, F., & Dunn-Walters, D. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.602539 · Cited by 161
Psoriasis and Systemic Inflammatory Disorders
Tashiro, T., & Sawada, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084457 · Cited by 104
Endothelial Dysfunction as the Common Pathway Linking Obesity, Hypertension and Atherosclerosis
Młynarska, E., Bojdo, K., Frankenstein, H., Krawiranda, K., Kustosik, N., Lisińska, W., Rysz, J., & Franczyk, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010096 · Cited by 87
Metadata
- Authors
- von Stebut, E., Boehncke, W.-H., Ghoreschi, K., Gori, T., Kaya, Z., Thaci, D., & Schäffler, A.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-01-15
- Volume
- 10
- Pages
- 3096-3096
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2999565226
- Cited by
- 199
- References
- 21
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.